Albumin-Adjusted Serum Calcium Levels Higher with Tumor Malignancy
the Cancer Therapy Advisor take:
Albumin-adjusted serum calcium was reported to be significantly greater in women with malignant tumors, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in this study included 514 women who underwent resection at Wake Forest University Baptist Medical Center (July 2009-June 2013) for pelvic masses. The patients were divided into a “training” set and a “testing” set (to identify data associations and to provide confirmation of these associations, respectively).
Results showed women with malignant masses had significantly greater levels of albumin-adjusted serum calcium levels compared to those with benign masses (P=0.0004).
High normocalcemia (ie, an albumin-adjusted serum calcium ≥10 mg/dL) was reported in 53% of women with malignant tumors compared with 12% in those with benign tumors. Furthermore, the high normocalcemia correlated to an increased risk of malignancy of approximately 14-fold.
The study suggests serum albumin and calcium could be an economic and sensitive method to predict malignancy of tumors in women with pelvic masses.
Albumin-adjusted serum calcium was reported to be significantly greater in women with malignant tumors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Plastics and Cancer
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer